Juneja Deven, Savio Raymond D, Srinivasan Shrikanth, Pandit Rahul A, Ramasubban Suresh, Reddy Pavan K, Singh Manoj, Gopal Palepu Bn, Chaudhry Dhruva, Govil Deepak, Dixit Shubhal, Samavedam Srinivas
Institute of Critical Care Medicine, Max Super Speciality Hospital, New Delhi, India.
Department of Critical Care Medicine, Apollo Hospitals, Chennai, Tamil Nadu, India.
Indian J Crit Care Med. 2020 Nov;24(Suppl 5):S244-S253. doi: 10.5005/jp-journals-10071-23601.
With more than 23 million infections and more than 814,000 deaths worldwide, the coronavirus disease-2019 (COVID-19) pandemic is still far from over. Several classes of drugs including antivirals, antiretrovirals, anti-inflammatory, immunomodulatory, and antibiotics have been tried with varying levels of success. Still, there is lack of any specific therapy to deal with this infection. Although less than 30% of these patients require intensive care unit admission, morbidity and mortality in this subgroup of patients remain high. Hence, it becomes imperative to have general principles to guide intensivists managing these patients. However, as the literature emerges, these recommendations may change and hence, frequent updates may be required. Juneja D, Savio RD, Srinivasan S, Pandit RA, Ramasubban S, Reddy PK, . Basic Critical Care for Management of COVID-19 Patients: Position Paper of Indian Society of Critical Care Medicine, Part-I. Indian J Crit Care Med 2020;24(Suppl 5):S244-S253.
新型冠状病毒肺炎（COVID-19）大流行在全球已造成超过2300万例感染和超过81.4万例死亡，目前仍远未结束。包括抗病毒药物、抗逆转录病毒药物、抗炎药物、免疫调节药物和抗生素在内的几类药物都曾尝试使用，取得的成效各异。然而，仍然缺乏针对这种感染的特效疗法。虽然这些患者中不到30% 需要入住重症监护病房，但这一亚组患者的发病率和死亡率仍然很高。因此，制定指导重症监护医生管理这些患者的一般原则变得势在必行。然而，随着文献的不断涌现，这些建议可能会发生变化，因此可能需要频繁更新。Juneja D，Savio RD，Srinivasan S，Pandit RA，Ramasubban S，Reddy PK等。COVID-19患者管理的基础重症护理：印度重症监护医学学会立场文件，第一部分。《印度重症监护医学杂志》2020年；24（增刊5）：S244 - S253。
